NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NXTC stock has decreased by 75.5% and is now trading at $9.37.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.03. NextCure had a negative net margin of 65.22% and a negative return on equity of 8.79%.
View NextCure's earnings history.

9 equities research analysts have issued 1 year price objectives for NextCure's shares. Their forecasts range from $11.00 to $87.00. On average, they expect NextCure's stock price to reach $32.70 in the next year. This suggests a possible upside of 249.0% from the stock's current price.
View analysts' price targets for NextCure.

Headlines about NXTC stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a news impact score of -4.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about NextCure.

NextCure saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,740,000 shares, an increase of 41.5% from the May 31st total of 1,230,000 shares. Based on an average daily volume of 301,900 shares, the short-interest ratio is presently 5.8 days. Currently, 10.7% of the company's stock are sold short.
View NextCure's Short Interest.

Some companies that are related to NextCure include Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA), Stoke Therapeutics (STOK), Athenex (ATNX), Retrophin (RTRX), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Generation Bio (GBIO), Legend Biotech (PLRX), Aimmune Therapeutics (AIMT) and Gossamer Bio (GOSS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT), BioNano Genomics (BNGO) and Novan (NOVN).

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%), Bank of New York Mellon Corp (0.22%), Vident Investment Advisory LLC (0.20%), Vident Investment Advisory LLC (0.20%) and Asymmetry Capital Management L.P. (0.18%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Asymmetry Capital Management L.P., SG Americas Securities LLC, Swiss National Bank, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Bank of New York Mellon Corp, and Bessemer Group Inc.. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $9.37.

NextCure has a market capitalization of $257.83 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]